LUBIPROSTONE (lubiprostone) by Ascentage Pharma is chloride channel activators [moa]. Approved for chronic idiopathic constipation (cic) in adults, opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer and 3 more indications. First approved in 2025.
Drug data last refreshed 20h ago
Chloride Channel Activators
Chloride Channel Activator
Worked on LUBIPROSTONE at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Lubiprostone to Treat Constipation
Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers
Lubiprostone for Chronic Idiopathic Constipation Treatment
Lubiprostone for Treatment of Chronic Idiopathic Constipation
Lubiprostone for the Treatment of Chronic Idiopathic Constipation